COX-2 inhibitors (Q77937806)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9929039%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

title

COX-2 inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9929039%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

author name string

C J Hawkey

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9929039%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

language of work or name

English

0 references

publication date

1 January 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9929039%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9929039%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

volume

353

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9929039%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

page(s)

307-314

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9929039%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

issue

9149

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9929039%20AND%20SRC:MED&resulttype=core&format=json

The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1

9 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Investigation of the binding of isoform-selective inhibitors to prostaglandin endoperoxide synthases using fluorescence spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

1 reference

7 January 2021

A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Safety of meloxicam: a global analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthriti

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

NSAIDs, Cox-2 inhibitors, and the gut

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Effects of nabumetone on prostanoid biosynthesis in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Review article: COX-II inhibitors--a new generation of safer NSAIDs?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Effects of some naturally occurring prostanoids and some cyclooxygenase inhibitors on the contractility of the human lower uterine segment in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Disruption of cyclooxygenase genes in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Future treatments for arthritis: new NSAIDs, NO NSAIDs, or no NSAIDs?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912154-2

7 January 2021

10.1016/S0140-6736(98)12154-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9929039%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference